

Data Sharing Statement

Article Info	https://dx.doi.org/10.21037/atm-22-3781	
Item	Question	Authors' Response (place "-" if not applicable)
1	Would you like to share data collected for your study to others?	Yes.
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	The data of bergenin on inhibiting pancreatic β -cell inflammatory death will be shared.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Study protocol and statistical analysis plan will be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date, since the technique may be updated over time.
7	To whom will you share the data?	Cardiovascular disease specialist and scholars who are interested in studies of bergenin.
8	For what type of analysis or purpose?	For analysis to evaluate the safety and dose of bergenin in treating cardiovascular disease in vivo and in clinical studies.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: ccx6255@126.com; 164231074@qq.com.
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.